 CHARLESTON, S.C., Feb. 19, 2021 GLOBE NEWSWIRE -- Aeterna Zentaris Inc. NASDAQ: AEZS TSX: AEZS Aeterna or the Company, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the closing of its previously announced public offering of 20,509,746 common shares of Aeterna, at a price to the public of 1.45 per share. The gross proceeds from the offering were approximately 29.7 million, before deducting underwriting discounts, commissions and offering expenses payable by Aeterna. 